“We believe that next generation vaccines will be crucial in
the continued fight against COVID-19,’’ GSK chief executive Emma Walmsley said,
noting that the joint venture builds on an existing partnership between the two
companies.
They plan to combine their “scientific expertise in mRNA and
vaccine development to advance and accelerate the development of new COVID-19
vaccine candidates,’’ Walmsley said.
In addition, GSK is to support CureVac in producing its
first generation vaccines with the manufacture of 100 million doses in 2021,
according to a joint statement.
CureVac’s current COVID-19 vaccine is in phase 2b/3 of its
clinical testing and could be submitted to regulators for approval in a matter
of months.
As part of the collaboration, GSK is to make an upfront
payment of 75 million euros (90 million dollars) and a further milestone
payment of 75 million euros, “conditional on the achievement of specific
milestones,’’ the statement said.
0 comments:
Post a Comment